Also known as Pegylated MGF · PEG Mechano Growth Factor · PEG-IGF-1Ec
A pegylated form of Mechano Growth Factor (MGF) designed for a longer half-life than the native IGF-1Ec splice peptide.
Research refreshed
PEG-MGF is Mechano Growth Factor — the IGF-1Ec splice variant released by mechanically loaded muscle — with a polyethylene-glycol (PEG) chain attached to extend its short half-life. Native MGF is cleared very quickly, so pegylation is used in research settings to keep the peptide in circulation long enough to study its proposed role in activating muscle satellite cells and local repair. It is a research compound, profiled here as the long-acting form of MGF; see the MGF entry for the underlying biology. It is not FDA-approved.
MGF is the locally acting splice variant of IGF-1 that muscle produces in response to mechanical load; its distinctive E-domain is thought to activate the satellite cells that repair and grow muscle. Its practical problem as a research tool is speed of clearance — native MGF disappears from circulation almost immediately.
Pegylation is the standard fix: attaching a PEG chain shields the peptide and slows its removal, giving a longer-lived version for study. PEG-MGF is that long-acting form. The biology it is probing is MGF’s, and the evidence is preclinical; it is not FDA-approved. This page is a research and educational reference.
Same MGF signal — satellite-cell activation and local muscle repair via the E-domain of the IGF-1Ec splice variant — with a PEG chain that slows renal clearance and proteolysis to extend circulating half-life.
Behind every vial of PEG-MGF is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how PEG-MGF, specifically, is brought into being.
PEG-MGF begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
PEG-MGF is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries PEGylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — PEG-MGF plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of PEG-MGF proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of PEG-MGF — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
The MGF backbone is a ~24-residue peptide made by solid-phase synthesis, but the hard, poorly-standardized step is the PEG conjugation — the attachment site and PEG size determine the product, and “PEG-MGF” materials vary widely in how (and whether) the PEG is actually coupled. Identity work has to characterize the conjugate, not just the peptide, which is rarely disclosed on product pages.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning PEG-MGF, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Mechano Growth Factor (the IGF-1Ec splice peptide) with a PEG chain attached to extend its otherwise very short half-life for research use.
Native MGF is cleared almost immediately; the PEG chain slows clearance and proteolysis so the peptide stays in circulation long enough to study.
Same signaling peptide and proposed biology — the difference is the pegylation that makes PEG-MGF longer-acting. See the MGF entry for the base science.
No — it is a research compound, not FDA-approved. This page is a research and educational reference.
Recombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewA long-acting modified IGF-1 analog with reduced IGFBP binding and prolonged systemic activity.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.